Telix Pharmaceutical/$TLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Telix Pharmaceutical
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Ticker
$TLX
Sector
Primary listing
Employees
1,152
Headquarters
North Melbourne, Australia
Website
TLX Metrics
BasicAdvanced
$3.3bn
-
-$0.02
0.59
-
Price and volume
Market cap
$3.3bn
Beta
0.59
52-week high
$17.30
52-week low
$6.28
Average daily volume
161k
Financial strength
Current ratio
1.426
Quick ratio
1.21
Long term debt to equity
107.962
Total debt to equity
112.454
Interest coverage (TTM)
1.40%
Profitability
EBITDA (TTM)
32.46
Gross margin (TTM)
47.51%
Net profit margin (TTM)
-0.89%
Operating margin (TTM)
2.40%
Effective tax rate (TTM)
-35.30%
Revenue per employee (TTM)
$700,000
Management effectiveness
Return on assets (TTM)
1.15%
Return on equity (TTM)
-1.85%
Valuation
Price to revenue (TTM)
4.01
Price to book
11.25
Price to tangible book (TTM)
-26.33
Price to free cash flow (TTM)
-52.783
Free cash flow yield (TTM)
-1.89%
Free cash flow per share (TTM)
-0.181
Growth
Revenue change (TTM)
55.61%
Earnings per share change (TTM)
-121.62%
3-year revenue growth (CAGR)
95.98%
3-year earnings per share growth (CAGR)
-54.46%
TLX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs